AUSTRALIAN Securities Exchange (ASX) listed medtech firm, MedAdvisor (MDR), is continuing its growth on the back of a strong performance in the 2022 Financial Year, CEO, Rick Ratliff, told investors.
Speaking at the company's annual general meeting this morning, Ratliff said MDR's near-term priorities included completing the integration of GuildLink to drive further scale and efficiencies, and to grow its digital solutions in the US to boost revenue and improve margins.
Ratliff noted that the business signed an initial two-year agreement with a pharmacy software group that represents more than 10,000 stores in the US, increasing MDR's presence in the US to 30,000 pharmacy locations.
He added that MDR was aiming to complete its roll out in New Zealand to strengthen its market position and grow software as a solution (SAAS) revenue.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Nov 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Nov 22
